CONSOLI, Ugo
 Distribuzione geografica
Continente #
NA - Nord America 139
AS - Asia 82
EU - Europa 66
SA - Sud America 19
AF - Africa 15
OC - Oceania 2
Totale 323
Nazione #
US - Stati Uniti d'America 135
SG - Singapore 43
IT - Italia 38
CN - Cina 23
BR - Brasile 16
IE - Irlanda 15
CI - Costa d'Avorio 13
KR - Corea 9
CA - Canada 3
FI - Finlandia 3
AU - Australia 2
FR - Francia 2
IN - India 2
PL - Polonia 2
RU - Federazione Russa 2
AR - Argentina 1
AT - Austria 1
AZ - Azerbaigian 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
GB - Regno Unito 1
IL - Israele 1
IQ - Iraq 1
MX - Messico 1
NL - Olanda 1
SA - Arabia Saudita 1
UA - Ucraina 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 323
Città #
Santa Clara 47
Singapore 29
Chicago 15
Dublin 15
Chandler 14
Hefei 14
Abidjan 13
Civitanova Marche 12
Seoul 9
Ashburn 7
Boardman 6
Aci Castello 4
Catania 4
Los Angeles 4
Andover 3
Cambridge 3
Lawrence 3
Turku 3
Belpasso 2
Campinas 2
Des Moines 2
Genoa 2
New York 2
Palermo 2
Phoenix 2
Rome 2
Algiers 1
Alvorada 1
Amsterdam 1
Baku 1
Beijing 1
Belo Horizonte 1
Bogotá 1
Boston 1
Brasília 1
Brooklyn 1
Calvisano 1
Curitiba 1
Dallas 1
Dammam 1
Erbil 1
Fuzhou 1
Guayaquil 1
Johannesburg 1
Kochi 1
Limoeiro de Anadia 1
Macaúbas 1
Melzo 1
Mexico City 1
Montreal 1
Osasco 1
Paris 1
Phủ Lý 1
Piracicaba 1
Planalto 1
Ponta Grossa 1
Pune 1
Richmond 1
Saint Petersburg 1
Santaluz 1
São Félix do Xingu Municipality 1
Tel Aviv 1
Vancouver 1
Vigia 1
Villa Constitución 1
Várzea Grande 1
Warsaw 1
Wilmington 1
Totale 263
Nome #
Mucorales/Fusarium Mixed Infection in Hematologic Patient with COVID-19 Complications: An Unfortunate Combination 79
Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors 67
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study 64
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 51
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 48
Enhanced percent age of leu m3+dr+ and leu m3+cd25+ cells in newly diagnosed iddm patients 24
Totale 333
Categoria #
all - tutte 1.351
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.351


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 4 0 0 2 0 0
2021/202215 0 3 0 0 3 0 3 0 1 0 0 5
2022/202355 3 6 1 2 3 4 1 10 19 0 4 2
2023/202447 1 9 3 3 8 7 0 1 0 3 7 5
2024/2025161 5 21 6 17 35 20 0 4 17 8 16 12
2025/202649 22 25 2 0 0 0 0 0 0 0 0 0
Totale 333